In this role, Barry will be responsible for leading operations, communicating and implementing company mission, and guiding overall strategy, direction, and growth.
Previously, Barry served as the vice president of applied genomics at Illumina (NASDAQ: ILMN) where she integrated market development strategies with product and business model innovation to accelerate the application of genomics in medicine and personal healthcare.
Prior to Illumina, Barry spent seven years at Genaissance Pharmaceuticals, one of the first genomics startups focused on individualized medicine and DNA-based diagnostic testing, with the primary responsibility of promoting clinical genetics testing services for pharmaceutical clinical trials.
She holds a BS in biology from the University of Vermont and a MBA from the University of Connecticut School of Business.
Luna DNA is a genomic and medical research database powered by the blockchain and owned by its community. A Public Benefit Corp., Luna DNA enables people to own and share their genomic information for the greater good of the community and medical research.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval